Current Report Filing (8-k)
December 23 2019 - 5:00PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
December 18, 2019
Predictive Oncology Inc.
(Exact name of registrant as specified in
charter)
Delaware
|
|
001-36790
|
|
83-4360734
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
2915 Commers Drive, Suite 900
Eagan, Minnesota 55121
(Address of principal executive offices)
(651) 389-4800
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
from last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240. 13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, $0.01 par value
|
POAI
|
Nasdaq Capital Market
|
Item 5.07 Submission of Matters to a
Vote of Security Holders.
At the annual meeting
of stockholders on December 18, 2019, Predictive Oncology Inc.’s (the “Company”) stockholders took the following
actions:
|
(i)
|
The stockholders elected one Class I member, Thomas J. McGoldrick, to the Board of Directors by
a plurality of the votes. There were 444,931 votes cast for Mr. McGoldrick and 824,500 withheld.
|
|
(ii)
|
The stockholders did not approve a non-binding advisory resolution to approve compensation of the
Company’s executive officers. There were 429,964 votes for the proposal; 838,882 votes against; 585 votes abstained; and
there were 918,671 broker non-votes.
|
|
(iii)
|
The stockholders did not approve an Amended and Restated 2012 Stock Incentive Plan, including an
increase in the reserve of shares of common stock authorized for issuance thereunder by 600,000 to 1,600,000. There were 409,432
votes for the proposal; 846,354 votes against; 13,645 votes abstained; and there were 918,671 broker non-votes.
|
|
(iv)
|
The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's registered
public accounting firm for the fiscal year ending December 31, 2019. There were 2,129,820 votes for the proposal; 56,235 votes
against; and 2,047 votes abstained.
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: December 23, 2019
|
PREDICTIVE ONCOLOGY INC.
|
|
|
|
|
|
By:
|
/s/ Bob Myers
|
|
|
|
Bob Myers
|
|
|
|
Chief Financial Officer
|
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2024 to May 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From May 2023 to May 2024